Update on progress in the treatment of breast cancer patients
Breast cancer is one of the most prevalent malignant tumours in women worldwide, and in recent years there have been notable new advances in its treatment. Precision medical and target-oriented treatments in breast cancer treatments have become new highlights. For example, a new generation of Her-2-positive breast cancers is emerging. Antibodies – Drugs of the ADC type, such as Enmétratos, which is one-sided, can deliver cytotoxic drugs to the HeR – 2 positive tumour cells and reduce damage to normal cells while improving their efficacy. In the case of late Her – 2 positive breast cancer patients, this drug has significantly increased the duration of life and improved the quality of life of the patients. For triple-negative breast cancer, new targets and corresponding target-oriented treatment drugs are also being studied and applied. Among them, the polythyroid nucleophosphate (PARP) inhibitor for a mutation of the BRCA1/2 gene has shown good therapeutic effects in clinical trials, giving new hope to this difficult subtype breast cancer patient. Immunotherapy has also made significant progress in the area of breast cancer. Immunosuppressants, such as the Pablo Monovalent, show persistent anti-tumour activity among some breast cancer patients. In particular, in the case of triple-negative breast cancer and some breast cancers with high tumour mutation loads, tumours are activated by removing tumour cells from the immune system. At present, several clinical trials are exploring the best options for joint application of immunotherapy and other treatments (e.g. chemotherapy, target-oriented treatment) to further improve the efficacy of treatment. Optimization of new assisted treatments is increasingly important in the treatment of breast cancer. Pre-operative chemotherapy, target-oriented treatment or endocrine treatment can reduce tumours, increase surgical hysterectomy and breast milk. Newly assisted treatment programmes are now more individualized. For example, the most appropriate combination of drugs is selected on the basis of the patient ‘ s genetic test results and tumour characteristics. At the same time, the post-auxiliary efficacy assessment tools are more precise, such as the long-term prediction of patients through a full pathological relief (pCR) and further guidance for follow-up treatment decisions, whether to continue with the original treatment consolidation or adjustment programme. Innovations in radiotherapy are constantly improving in radiotherapy. Technologies such as enhanced radiotherapy (IMRT) and volume rotation (VMAT) can more precisely concentrate radiation doses on the tumor, reduce exposure to normal surrounding tissues (such as the heart, lungs, etc.), reduce the incidence of adverse effects associated with release, such as radiopneumonia, heart damage, etc., and increase patient tolerance to release. Overall, recent advances in breast cancer treatment have brought more treatment options and better planning to patients. These advances have benefited from in-depth basic medical research, clinical research and the development of a multidisciplinary collaborative treatment model, which has increased the confidence of breast cancer patients in the fight against disease.
Breast cancer
